CA2932846A1 - Methods for the prognosis of breast cancer - Google Patents

Methods for the prognosis of breast cancer Download PDF

Info

Publication number
CA2932846A1
CA2932846A1 CA2932846A CA2932846A CA2932846A1 CA 2932846 A1 CA2932846 A1 CA 2932846A1 CA 2932846 A CA2932846 A CA 2932846A CA 2932846 A CA2932846 A CA 2932846A CA 2932846 A1 CA2932846 A1 CA 2932846A1
Authority
CA
Canada
Prior art keywords
icd
nuclear
score
breast cancer
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2932846A
Other languages
English (en)
French (fr)
Inventor
Paul Walfish
Ranju Ralhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/099,529 external-priority patent/US20140187438A1/en
Priority claimed from US14/501,020 external-priority patent/US20150094224A1/en
Application filed by Individual filed Critical Individual
Publication of CA2932846A1 publication Critical patent/CA2932846A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2932846A 2013-12-06 2014-12-05 Methods for the prognosis of breast cancer Abandoned CA2932846A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/099,529 US20140187438A1 (en) 2010-05-04 2013-12-06 Methods and Compositions for the Diagnosis and Treatment of Epithelial Cancers
US14/099,529 2013-12-06
US14/501,020 2014-09-29
US14/501,020 US20150094224A1 (en) 2010-05-04 2014-09-29 Methods for the diagnosis or prognosis of breast cancer
PCT/CA2014/051176 WO2015081446A1 (en) 2013-12-06 2014-12-05 Methods for the prognosis of breast cancer

Publications (1)

Publication Number Publication Date
CA2932846A1 true CA2932846A1 (en) 2015-06-11

Family

ID=53272695

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2932846A Abandoned CA2932846A1 (en) 2013-12-06 2014-12-05 Methods for the prognosis of breast cancer

Country Status (5)

Country Link
EP (1) EP3077812A4 (enExample)
JP (1) JP2017500590A (enExample)
AU (1) AU2014360606A1 (enExample)
CA (1) CA2932846A1 (enExample)
WO (1) WO2015081446A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601505B2 (en) * 2003-05-29 2009-10-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20110097732A1 (en) * 2009-10-26 2011-04-28 Medinnova As Novel biomarker for the prognosis of breast cancer
WO2011137513A1 (en) * 2010-05-04 2011-11-10 Paul Walfish Method for the diagnosis of epithelial cancers by the detection of epicd polypeptide

Also Published As

Publication number Publication date
JP2017500590A (ja) 2017-01-05
WO2015081446A1 (en) 2015-06-11
EP3077812A4 (en) 2017-06-07
EP3077812A1 (en) 2016-10-12
WO2015081446A9 (en) 2016-03-31
AU2014360606A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
EP1800130B1 (en) Methods and compositions for evaluating breast cancer prognosis
Botti et al. Programmed death ligand 1 (PD-L1) expression in primary angiosarcoma
EP2494351B1 (en) Colon and rectal tumor markers and methods of use thereof
Cao et al. RACK1: A superior independent predictor for poor clinical outcome in breast cancer
JP2009536355A (ja) 診断指標または予測指標としての細胞内局在プロフィールの使用
US20120052071A1 (en) Tumor markers and methods of use thereof
US8377648B2 (en) Autoimmune regulation of prostate cancer by annexin A3
Ba et al. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis
US20080166733A1 (en) Method for determining the prognosis of cancer patients by measuring levels of bag expression
Liang et al. Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis
EP2494361B2 (en) Ovary tumor markers and methods of use thereof
Martínez-Aguilar et al. Label-free selected reaction monitoring enables multiplexed quantitation of S100 protein isoforms in cancer cells
WO2012154722A1 (en) Predictive biomarkers for prostate cancer
US20160313335A1 (en) Methods for the Prognosis of Breast Cancer
WO2011010309A1 (en) A method of diagnosing cancer
JP2012501440A (ja) 内分泌処置予測因子としてのａｎｌｎタンパク質
CN103180455B (zh) 侦测致死系统的方法及其用途
Charpin et al. Automated and quantitative immunocytochemical assays of Nm23/NDPK protein in breast carcinomas
Madeira et al. Comparison of immunohistochemical analysis with estrogen receptor SP1 and 1D5 monoclonal antibodies in breast cancer
EP2895863A1 (en) New biomarkers for the diagnosis and/or prognosis of clear cell renal cell carcinoma
CA2932846A1 (en) Methods for the prognosis of breast cancer
CN111208304B (zh) 肿瘤来源IgG在甲状旁腺癌诊断和预后中的用途
EP2269073B1 (en) A method of assessing cancer status in a breast cancer patient
Sundblad et al. Metallopanstimulin/S27 ribosomal antigen expression in stages I and II breast cancer: its relationship with clinicopathologic factors
WO2016106453A1 (en) Nuclear ep-icd as a prognosis marker for prostate cancer

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20191205